FAP and prostate cancer: For example, intratumoral injection of an FAP-activated protoxin produced significant lysis and growth inhibition of human breast and prostate cancer xenografts with minimal toxicity to the host animal [45], while genetic deletion and pharmacologic inhibition of FAP inhibited tumor growth in both mouse models of lung and colon cancer [47].